AR080888A1 - Uso de un derivado de acido graso para producir una composicion oftalmica - Google Patents

Uso de un derivado de acido graso para producir una composicion oftalmica

Info

Publication number
AR080888A1
AR080888A1 ARP110101238A ARP110101238A AR080888A1 AR 080888 A1 AR080888 A1 AR 080888A1 AR P110101238 A ARP110101238 A AR P110101238A AR P110101238 A ARP110101238 A AR P110101238A AR 080888 A1 AR080888 A1 AR 080888A1
Authority
AR
Argentina
Prior art keywords
subject
program
temperature
patient
central area
Prior art date
Application number
ARP110101238A
Other languages
English (en)
Spanish (es)
Inventor
Yukihiko Mashima
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AR080888A1 publication Critical patent/AR080888A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
ARP110101238A 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica AR080888A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32334210P 2010-04-12 2010-04-12
US32333810P 2010-04-12 2010-04-12
US32681110P 2010-04-22 2010-04-22
US36294510P 2010-07-09 2010-07-09
US40823710P 2010-10-29 2010-10-29

Publications (1)

Publication Number Publication Date
AR080888A1 true AR080888A1 (es) 2012-05-16

Family

ID=44798822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101238A AR080888A1 (es) 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica

Country Status (9)

Country Link
US (2) US20110275715A1 (enExample)
EP (2) EP2558104A4 (enExample)
JP (3) JP5686819B2 (enExample)
KR (2) KR20130050939A (enExample)
CN (2) CN102946883A (enExample)
AR (1) AR080888A1 (enExample)
CA (2) CA2795723A1 (enExample)
TW (2) TW201141486A (enExample)
WO (2) WO2011129457A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120096555A (ko) * 2009-11-27 2012-08-30 가부시키가이샤 아루떼꾸 우에노 안구 건조증 및/또는 각결막 장해의 처치에 유용한 약제의 스크리닝 방법 및 그 방법에 의해 얻어진 의약 조성물
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
EP2817031A4 (en) * 2012-02-22 2015-08-05 Tufts College COMPOSITIONS AND METHOD FOR THE ORGANIC ADMINISTRATION OF A THERAPEUTIC ACTIVE SUBSTANCE
WO2018036498A1 (en) * 2016-08-24 2018-03-01 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
EP3946467A1 (en) * 2019-04-03 2022-02-09 REGENXBIO Inc. Gene therapy for eye pathologies
IL292350A (en) 2019-10-30 2022-06-01 Perfuse Therapeutics Inc Treatment of ocular diseases using endothelin receptor antagonists
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
PE20240775A1 (es) 2021-07-09 2024-04-17 Aligos Therapeutics Inc Compuestos antivirales
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251862B1 (en) * 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
ES2431640T3 (es) * 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
EP2558104A1 (en) 2013-02-20
KR20130099812A (ko) 2013-09-06
JP5686819B2 (ja) 2015-03-18
JP2013528563A (ja) 2013-07-11
JP2016026182A (ja) 2016-02-12
US20110275711A1 (en) 2011-11-10
JP5878128B2 (ja) 2016-03-08
EP2558103A1 (en) 2013-02-20
TW201141486A (en) 2011-12-01
EP2558104A4 (en) 2013-12-11
WO2011129457A1 (en) 2011-10-20
CN102933217A (zh) 2013-02-13
CN102946883A (zh) 2013-02-27
JP2013523601A (ja) 2013-06-17
CA2795720A1 (en) 2011-10-20
WO2011129461A1 (en) 2011-10-20
CA2795723A1 (en) 2011-10-20
EP2558103A4 (en) 2013-09-25
KR20130050939A (ko) 2013-05-16
TW201204366A (en) 2012-02-01
US20110275715A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
AR080888A1 (es) Uso de un derivado de acido graso para producir una composicion oftalmica
Benito et al. Objective optical assessment of tear-film quality dynamics in normal and mildly symptomatic dry eyes
Colak et al. Comparison of corneal topographic measurements and high order aberrations in keratoconus and normal eyes
Orucoglu et al. Analysis of age, refractive error and gender related changes of the cornea and the anterior segment of the eye with Scheimpflug imaging
Wolsley et al. Investigation of changes in the myopic retina using multifocal electroretinograms, optical coherence tomography and peripheral resolution acuity
Pinero et al. Ocular scattering
Low et al. The outcomes of primary pediatric keratoplasty in Singapore
BR112013021153A2 (pt) dispositivo e métodos de rastreamento ocular de fotorrefração
León et al. A comparison of the reliability of dynamic retinoscopy and subjective measurements of amplitude of accommodation
Dysli et al. Fluorescence lifetime imaging in retinal artery occlusion
Read Ocular and environmental factors associated with eye growth in childhood
Loreck et al. Morning myopic shift and glare in advanced Fuchs endothelial corneal dystrophy
Nguyen et al. Aberrometry repeatability and agreement with autorefraction
Hilmi et al. Measurement of contrast sensitivity using the M&S Smart System II compared with the standard Pelli–Robson chart in patients with primary pterygium
Chakraborty et al. Diurnal variations in ocular aberrations of human eyes
Hussein et al. The long-term outcomes in children who are not compliant with spectacle treatment for accommodative esotropia
Qiao et al. Full-field strain mapping for characterization of structure-related variation in corneal biomechanical properties using digital image correlation (DIC) technology
Gillmann et al. Relationship between contact lens sensor output parameters and visual field progression in open-angle glaucoma: assessment of a practical tool to guide clinical risk-assessment
Ortiz et al. Quantification and monitoring of visual disturbances for patients with cataracts using Halo v1. 0 software.
van Bree et al. Straylight values after refractive surgery: screening for ocular fitness in demanding professions
Chen et al. Comparison of wavefront aberrations in rabbit and human eyes
Arranz-Márquez et al. Disminución de la agudeza visual
ES2441669A1 (es) Método para la detección de pérdidas de función visual.
Kuo et al. The ocular biometric and corneal topographic characteristics of high-anisometropic adults in Taiwan
O'Connell et al. Provocative intraocular pressure challenge preferentially decreases venous oxygen saturation despite no reduction in blood flow

Legal Events

Date Code Title Description
FB Suspension of granting procedure